MAPS Submits Protocol Amendment 4, Version 1 to FDA for MJP2 Phase 2 Study
On January 30, 2026, the Multidisciplinary Association for Psychedelic Studies (MAPS) submitted MJP2 Protocol Amendment 4, Version 1 (A4V1) to the U.S. Food and Drug Administration (FDA) for review. This amendment was developed to complete administrative and operational refinements in advance of study initiation. Amendment 4, Version 1 updates the previously cleared smoking-only protocol (A3V1) and was… Continue reading MAPS Submits Protocol Amendment 4, Version 1 to FDA for MJP2 Phase 2 Study
External link. We are not responsible for the content.
Read more ↗More From MAPS
Protected: MAPS Publishes Ibogaine Investigator’s Brochure as a Free, Open-Access Resource
There is no excerpt because this is a protected post.
Psychedelic Science 2027 Speaker Submission Invites the Field to Bridge Promise and Practice
June, 25, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the opening of speaker su...
MAPS Statement on the Supreme Court’s Ruling in United States v. Hemani
June 18, 2026 — In United States v. Hemani, the U.S. Supreme Court ruled today that the federal government’s prosecut...
Latest News
Psychedelics Today at the Aspen Psychedelic Symposium
Psychedelics Today founder Joe Moore hosted two panels at the Aspen Psychedelic Symposium, now available through Aspe...
The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit Model of Consciousness
Western clinical frameworks were built to reduce pathology, not to map what happens when a client encounters ancestra...
The Status Games Forrest Never Played
Welcome to The Psychedelic Blog.
Could Psychedelics Change Donald Trump?
We took a deep dive into the science of psychedelics and how they impact authoritarian attitudes. [...] Read More......
What Makes Music Psychedelic?
Repetition, Perception, and Form in the Music of Terry Riley
The State of Frontier Neuroscience: This is the century of the brain.
Why now, what’s investable & who wins.